Drugs / PEGylated Recombinant Human Hyaluronidase (PEGPH20)
PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03281369 | Oct 2017 → Oct 2025 | digestive system carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02910882 | Jan 2017 → Aug 2018 | pancreatic adenocarcinoma | Scripps Health | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2014-12-19 | Halozyme Therapeutics | Regulatory Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer halozyme.com ↗
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA), has designated PEGylated recombinant human hyaluronidase (PEGPH20) an orphan medicinal product for the treatment of pancreatic cancer. |
| 2014-10-03 | Halozyme Therapeutics | Regulatory Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer halozyme.com ↗
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-12-19 | Halozyme Therapeutics | Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer halozyme.com ↗ |
| 2014-10-03 | Halozyme Therapeutics | Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer halozyme.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGylated Recombinant Human Hyaluronidase (PEGPH20) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02910882 ↗ |
| Modality | Protein / enzyme biologic | “PEGylated recombinant human hyaluronidase (PEGPH20)” NCT03281369 ↗ |
| Route | Intravenous | “Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute” NCT02910882 ↗ |